TNF and Arthritis: To date, there are only limited data regarding the effects of anti-TNFα, anti-IL-1 or anti-RANKL therapies on systemic bone loss in arthritis patients [40], and there are no comparative data on the effects of these therapies on systemic markers or mediators of inflammation in either human or preclinical models.